ELSEVIER

Contents lists available at ScienceDirect

Pathology – Research and Practice

journal homepage: www.elsevier.com/locate/prp



Histologic characteristics of thymic adenocarcinomas: Clinicopathologic study of a nine-case series and a review of the literature



Ah-Young Kwon^a, Joungho Han^{a,*}, Jinah Chu^a, Yong Soo Choi^b, Byeong-Ho Jeong^c, Myung-Ju Ahn^d, Yong Chan Ahn^e

- ^a Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
- Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
- ^c Department of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
- d Department of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
- e Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

ARTICLE INFO

Article history: Received 12 August 2016

Keywords: Thymus Adenocarcinoma Subtype Mucin Immunohistochemistry

ABSTRACT

Primary thymic adenocarcinoma is an extraordinarily rare malignancy; only 49 cases have been reported in the medical literature to date. Because of its rarity, clinical and pathologic characteristics of thymic adenocarcinoma are unclear. We present nine cases of primary thymic adenocarcinoma and discuss clinicopathologic findings in the context of the existing literature.

Two-hundred twenty-six thymic carcinoma cases were diagnosed at Samsung Medical Center in Korea, from January, 2001 to July, 2016. Nine of these 226 cases were primary thymic adenocarcinomas. The mean age of primary thymic adenocarcinoma patients was 53.6 years, slightly younger than the mean age of patients with thymic squamous cell carcinomas. The male to female ratio was 2:1. Symptoms, if present, were usually due to compression by the tumor. Tumors showed an extra- or intra-cellular mucin and tubular growth pattern, with CK20- and CDX2-immunoreactivity, similar to adenocarcinomas of the lower intestinal tract.

Twenty-five previously reported cases, classified as mucinous adenocarcinoma and adenocarcinoma, not otherwise specified, also had similar characteristics to enteric-type adenocarcinoma and generally expressed CK20, CDX2, CEA, and/or MUC2. Some of these cases had a thymic cyst. These characteristics are different from those of papillary thymic carcinomas, which are morphologically similar to papillary thyroid carcinomas, express CK7 but not CK20, and are often associated with thymoma. The prognosis of thymic adenocarcinoma, enteric type appeared to be worse than the prognosis of papillary thymic carcinoma or carcinoma with adenoid cystic carcinoma-like features.

In summary, we demonstrated that common primary thymic adenocarcinomas show enteric-type differentiation with mucin. This tumor type has distinct clinical, pathological, immunohistochemical and prognostic characteristics and is different from other subtypes of thymic adenocarcinoma, papillary thymic carcinoma, and carcinoma with adenoid cystic carcinoma-like features.

 $\hbox{@ 2016}$ Elsevier GmbH. All rights reserved.

1. Introduction

Primary thymic adenocarcinoma is an extraordinarily rare malignancy. It is classified as papillary adenocarcinomas, mucinous

E-mail address: hanjho@skku.edu (J. Han).

adenocarcinomas, carcinomas with adenoid cystic carcinoma-like features, and not otherwise specified (NOS) types by the World Health Organization based on histologic morphology [1]. A total of 49 cases of primary thymic adenocarcinoma have been reported in the medical literature to date. Due to the rarity of this tumor, the clinical and pathologic characteristics of thymic adenocarcinoma are not well defined.

We present here nine cases of primary thymic adenocarcinoma. To identify the pathologic characteristics of primary thymic adenocarcinomas, we also reviewed the medical literature. We focused

^{*} Corresponding author at: Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, (06351) 81 Ilwon-ro, Gangnam-gu, Seoul, Republic of Korea.

Clinical features of the nine thymic adenocarcinomas cases.

1 1 1 1 2 2 2 2 2 2													
F 56 cough sputum N-S never smoker 7.6 III Normal serum CTX Syr3mon M 46 N-S HTND 20PY, current 6.4 IVB liver, lung, Elevated serum S+CTX+RTX 2yr 9mon M 51 shoulder and HTN DM 30PY, current 6.4 IVB liver, lung, Elevated serum RTX 1yr 2mon R 56 N-S Colon adeno-GRA 8.5PY, current 4.6 III N-S CTX Iyr 2mon M 50 chest wall pain HTN DM CVA 40PY, current 9.6 II N-S CRT 8mon M 50 chest wall loss Angina 20PY, current 8.1 IVB lung.spine N-S CTX+RTX 7mon M 62 chest monlort Argina mol HTN DM SPY, current 8.1 IVB bone (sacrum) N-S CTX+RTX 7mon R 6 chest monlort Alsomofort Bone (sacrum) N		Sex		Symptoms	History	Smoking history	Tumor size (cm)	Masaoka Stage	Metastasis	Associated findings	Treatment	Follow-up	Status
M 46 N-S HTN 20PY, current 10 III Elevated serum S-CTX+RTX 2y 9 mon A 51 shoulder and back pain HTN DM 30PY, current 6.4 IVB liver, lung, pinne Elevated serum RTX 1yr 2mon M 34 N-A Oclon adeno-carcinoma 8.5 PY, current 4.6 III N-B CTX 1yr M 70 chest wall pain HTN DM CVA 40PY, ex-smoker 8.1 IVB N-S CCRT 8mon M 50 chest wall pain HTN DM CVA 8.1 IVB Iung, spine N-S CTX+RTX 7mon M 50 chest wall pain HTN DM CVA 8.1 IVB Iung, spine N-S CTX+RTX 7mon M 50 chest wall pain HTN DM CVA 8.1 IVB bone (scalp) Elevated serum CTX F	#1	ш	56	cough sputum	N-S	never smoker	7.6	III		Normal serum CEA	CTx	5yr 3mon	DOD
M 51 shoulder and back pain HTN DM 30PY, current of back pain 6.4 IVB liver, lung, spine Elevated serum RTX 1yr Zmon M 34 N-A N-S 3PY, ex-smoker 11.9 IVB Spine CFA CTX 1yr F 56 N-A Colon adeno-gradinoma 8.5PY, current 4.6 III N-S CRY Brown M 70 chest wall pain HTN DM CVA 40PY, QPY 9.6 II N-S CRY Rmon M 50 chest wall pain HTN DM CVA 40PY, QPY 8.1 IVB N-S CTX + RTX 7mon M 50 chest wall pain HTN DM 5PY, current 3.2 IVB bone (scalp) Elevated serum CTX + RTX 7mon R 6 Chest chest HTN DM 5PY, current 3.2 IVB bone (scalp) CFA CTX Smon F 57 dyspnea rib HTN TN	#2	Σ	46	N-S	HTN	20PY, current	10	III		Elevated serum CEA	S + CTx + RTx	2yr 9mon	DOD
M 34 N-A N-S 3PY, ex-smoker 11.9 IVB spine N-S CTX 1yr F 56 N-S Colon adeno- 8.5PY, current 4.6 III N-S CRT 1yr 5mon M 70 chest wall pain HTN DM CVA 40PY, current 8.1 IVB N-S CRT 8mon M 50 chest Angina 20PY, current 8.1 IVB Iung. spine N-S CTX+RTX 7mon M 62 chest HTN DM 5PY, current 3.2 IVB bone (scalp) Elevated serum CTX 5mon F 57 dyspnearib HTN never smoker 5 IVB bone (sacrum) N-S CTX 5mon	#3	Σ	51	shoulder and back pain	HTN DM	30PY, current	6.4	IVB	liver, lung, spine	Elevated serum CEA	RTx	1yr 2mon	AWD
F 56 N-S Colon adeno- 8.5PY, current 4.6 III N-S S 1yr 5mon M 70 chest wall pain HTN DM CVA 40PY, current 9.6 II N-S CCRT 8mon M 50 chest Angina 20PY, current 8.1 IVB Iung, spine N-S CTX+RTX 7mon M 62 chest HTN DM 5PY, current 3.2 IVB bone (scalp) Elevated serum CTX 5mon F 57 dyspnearib HTN never smoker 5 IVB bone (sacrum) N-S CTX 5mon	#4	Σ	34	N-A	N-S	3PY, ex-smoker	11.9	IVB	spine	N-S	CTx	1yr	AWD
M 70 chest wall pain HTN DM CVA 40Py, ex-smoker 9.6 II N-S CCRT 8mon M 50 chest Angina 20Py, ex-smoker 8.1 IVB Iung, spine N-S CTX+RTX 7mon Weight loss	#2	ш	26	N-S	Colon adeno-	8.5PY, current	4.6	III		N-S	S	1yr 5mon	Progression (1vr) AWD
50 chest discomfort, discomfort, ex-smoker 8.1 IVB lung, spine N-S CTx+RTx 7mon weight loss (8 kg/2 mon) (8 kg/2 mon) (8 kg/2 mon) (9 kg/2 mon) Flevated serum CTx 5mon 62 chest discomfort HTN DM 5PY, current 3.2 IVB bone (scalp) Elevated serum CTx 5mon 57 dyspnea rib HTN never smoker 5 IVB bone (sacrum) N-S CTx 5mon	9#	Σ	70	chest wall pain	HTN DM CVA	40PY,	9.6	П		N-S	CCRT	8mon	Progression (5mon) AWD
O KBJZ MOH) M 62 chest ATN DM 5PY, current 3.2 IVB bone (scalp) Elevated serum CTX 5mon discomfort CEA Gyspnea rib HTN never smoker 5 IVB bone (sacrum) N-S CTX 5mon 5mon	47	Σ	20	chest discomfort, weight loss	Angina	20PY, ex-smoker	8.1	IVB	lung, spine	N-S	CTx + RTx	7mon	Progression (5mon), AWD
F 57 dyspnea-rib HTN never-smoker 5 IVB bone (sacrum) N-S CTx 5mon pain	8#	Σ	62	(o kg/z mon) chest discomfort	HTN DM	5PY, current	3.2	IVB	bone (scalp)	Elevated serum CEA	CTx	5mon	AWD
	6#	Ľ.	57	dyspnea rib pain	HTN	never smoker	2	IVB	bone (sacrum)	N-S	CTx	5mon	Progression (3mon), AWD

N-A, not available; partial regression.

on clinical characteristics, microscopic morphology, and immunohistochemical profiles of primary thymic adenocarcinomas.

2. Methods and materials

All 226 cases of thymic carcinoma were identified from the files of patients treated at Samsung Medical Center in Korea, from January, 2001 to July, 2016. Cases with the possibility of metastatic carcinoma or primary lung cancer were excluded based on clinical findings and pathologic review of a tumor in another organ or in the lungs or a TTF-1 positive-adenocarcinoma. A total of nine cases of primary thymic adenocarcinoma were identified. Clinical data, such as symptoms, history, and follow-up, were obtained by reviewing the respective clinical charts. Hematoxylin and eosin (H-E)-stained sections were reviewed, and immunohistochemical staining was performed using a Ventana automated immunostainer (Ventana, USA) if tissue sections were available. Primary antibodies used were CK7 (M7018: DAKO, Denmark), CK20 (M7019: DAKO). CDX2 (PA0535; Novocastra, UK), MUC2 (NCL-MUC-2; Leica Biosystems, UK), TTF-1 (M3575; DAKO), carcinoembryonic antigen (CEA, M7072; DAKO), CD5 (NCL-L-CD5-4C7; Leica Biosystems), and c-kit (A4502; DAKO). Kaplan-Meier survival analysis was used to compare survival among the subtypes of thymic adenocarcinoma. The study was approved by the Institutional Review Board of Samsung Medical Center.

3. Results

3.1. Epidemiology of thymic carcinomas

Two hundred twenty-six cases of thymic carcinoma were diagnosed at Samsung Medical Center from January, 2001 to July, 2016. One hundred ninety cases (84.1%) were diagnosed as thymic squamous cell carcinoma. Other cases were classified as large cell neuroendocrine carcinoma (10/226, 4.4%), small cell carcinoma (4/226, 1.8%), spindle cell neuroendocrine carcinoma (1/226, 0.4%), mucoepidermoid carcinoma (3/226, 1.3%), lymphoepitheliomalike carcinoma (2/226, 0.9%), clear cell carcinoma (1/226, 0.4%), sarcomatoid carcinoma (2/226, 0.9%), pleomorphic carcinoma (3/226, 1.3%), and undifferentiated carcinoma (1/226, 0.4%). Nine patients had thymic adenocarcinomas (9/226, 4.0%).

3.2. Clinical features of thymic adenocarcinoma

The clinical features of the nine cases are summarized in Table 1. Patients comprised six men and three women between 34 and 70 years of age. Mean age was 53.6 years. The chief complains were a non-symptomatic incidental mass (two cases) or non-specific symptoms of cough, dyspnea, or chest discomfort/pain. Some patients had chronic illnesses, such as hypertension (4/9), diabetes (3/9), and/or arrhythmia (1/9). One patient had undergone a right hemicolectomy due to colonic adenocarcinoma 3 years before discovery of the thymic mass. We reviewed the clinical evaluations and H-E slides of the colonic adenocarcinoma case to confirm the diagnosis of primary thymic mucinous adenocarcinoma. Seven patients had a smoking history (3–40 PYs, mean 18.07 PYs) and two were never-smokers.

Diagnostic imaging revealed an infiltrative mass in the anterior mediastinum, ranging in size from 3.2 to $11.9\,\mathrm{cm}$ (mean $7.4\,\mathrm{cm}$). In four of nine cases, the mediastinal masses contained calcification, and two of nine cases had a cystic portion on computed tomography (CT).

At the time of diagnosis, clinical stage was III or IV. Four patients had nodal metastasis (cN1) and five cases had distant metastasis (cM1) based on CT and whole-body positron emission tomography

Download English Version:

https://daneshyari.com/en/article/5529373

Download Persian Version:

https://daneshyari.com/article/5529373

<u>Daneshyari.com</u>